Replies to post #1685 on Insmed Inc (INSM)

[jellybean]

That was my take, but I'm confused because TRCA received their designation for IGFD last August (http://www.emea.eu.int/pdfs/human/comp/opinion/24763505en.pd, yet the COMP published a similar PR for Increlex in April with a review time of 87 days (http://www.emea.eu.int/pdfs/human/comp/12557206en.pdf).

Does that mean that it took them 87 days to review the Increlex Orphan drug status and that it was accepted? Is this what Chip Scarlett was referring to at minute 4:30 of the TRCA Q1:2006 CC?